The high specificity that occurred in all drug types indicates that Health Canada and the FDA are usually in broad agreement on which drugs should not have priority review status.
The high specificity that occurred in all drug types indicates thatHealth Canada and the FDA are usually in broad agreement onwhich drugs should not have priority review status.